TRPC6 channel blocker as potential therapeutics for pulmonal and renal diseases
The invention comprises diterpene derivatives for the treatment of pulmonary hypertension in conjunction with respiratory disorders, especially asthma and COPD. The pharmacological effect is mediated by selective block of TRPC6, a member of the subfamily of canonical transient receptor potential channels.
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
The Sound of the Perfect Coating
Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…
Customized silicon chips
…from Saxony for material characterization of printed electronics. How efficient are new materials? Does changing the properties lead to better conductivity? The Fraunhofer Institute for Photonic Microsystems IPMS develops and…
Acetylation: a Time-Keeper of glucocorticoid Sensitivity
Understanding the regulatory mechanism paves the way to enhance the effectiveness of anti-inflammatory therapies and to develop strategies to counteract the negative effects of stress- and age-related cortisol excess. The…